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Abstract
Background: Several reports on patients with chronic schizophrenia suggest that atypical versus typical antipsychotics are
expected to lead to better quality of life (QOL) and cognitive function. Our aim was to examine the association of chronic
treatment with typical or atypical antipsychotics with cognitive function, psychiatric symptoms, QOL, and drug-induced
extrapyramidal symptoms in long-hospitalized patients with schizophrenia.
Methodology and Principal Findings: The Hasegawa Dementia Scale-Revised (HDS-R), Brief Psychiatric Rating Scale (BPRS),
the Schizophrenia Quality of Life Scale, translated into Japanese (JSQLS), and the Drug-Induced Extrapyramidal Symptoms
Scale (DIEPSS) were used to evaluate cognitive function, psychiatric symptoms, QOL, and drug-induced extrapyramidal
symptoms. We examined the correlation between the dose of antipsychotics and each measure derived from these
psychometric tests. The student t-test was used to compare scores obtained from psychometric tests between patients
receiving typical and atypical antipsychotics. Results showed significant correlations between chlorpromazine (CPZ)-
equivalent doses of typical antipsychotics and atypical antipsychotics, and the total BPRS score and BPRS subscale scores for
positive symptoms. CPZ-equivalent doses of typical antipsychotics were correlated with the JSQLS subscale score for
dysfunction of psycho-social activity and DIEPSS score. Furthermore, the total BPRS scores, BPRS subscale score for positive
symptoms, the JSQLS subscale score for dysfunction of psycho-social activity, and the DIEPSS score were significantly higher
in patients receiving typical antipsychotics than atypical antipsychotics.
Conclusion and Significance: These findings suggest that long-term administration of typical antipsychotics has an
unfavorable association with feelings of difficulties mixing in social situations in patients with chronic schizophrenia.
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Introduction
The use of atypical antipsychotics in the treatment of
schizophrenia was introduced in Japan in 1996. Risperidone was
approved in June 1996, followed by perospirone and quetiapine in
February 2001, olanzapine in June 2001, aripiprazole in January
2006, and blonanserin in January 2008. After approval, risperi-
done was often used in addition to typical antipsychotics. Ongoing
experience revealed the efficacy of risperidone as monotherapy,
and this drug is currently one of the first-line agents used in the
treatment of schizophrenia [1]. Although atypical antipsychotics
have been recognized as first-line drugs in the treatment of
schizophrenia in Japan, in actual clinical practice, typical
antipsychotics are still prescribed to long-hospitalized patients
with schizophrenia [2,3]. Switching from typical antipsychotics to
atypical antipsychotics usually takes place in Japan when an
exacerbation of psychiatric symptoms is observed. In other words,
therapeutic agents are rarely changed if no problematic behaviors
are observed. Therefore, patients with chronic schizophrenia tend
to receive the same drug regimen for many years [4]. Long-term
administration of the same typical antipsychotic also makes it
difficult to taper anticholinergics that are used to alleviate adverse
effects induced by antipsychotics (e.g., extrapyramidal symptoms)
[5]. The combination of typical antipsychotics and anticholiner-
gics is often found in long-hospitalized patients with schizophrenia
in Japan. However, growing evidence demonstrates the unfavor-
able effects of typical antipsychotics and/or anticholinergics on
cognitive function [6–9]. Several reports focusing on inpatients
with chronic schizophrenia suggest that switching from typical to
atypical antipsychotics improves cognitive dysfunction [10–13].
In recent years, quality of life (QOL) has become an important
issue. Social and occupational impairments have long been
recognized as core features of schizophrenia affecting social
interactions, vocational and instrumental functioning skills, self-
care, and recreation [14]. Some cross-sectional studies of chronic
schizophrenia have suggested that psychopathology might be more
strongly correlated with community functioning than cognition
[15,16]. Various clinical factors related to QOL have been
reported. Several studies have suggested that depressed mood may
be the most important determinant of QOL [17–22]. Other
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symptoms, as well as the total severity of psychopathology [24],
help predict subjective QOL. Regarding the influence of
antipsychotics on QOL, Mortimer et al. reported that QOL is
genuinely superior with atypical agents even allowing for the
confounding effects of differential prescribing habits [25].
Furthermore, Ritsner et al. reported that both self-reported and
rater-observed QOL measures indicated superiority of atypical
over typical antipsychotic agents [26]. In the present study, we
focused on whether chronic administration of antipsychotics
influenced subjective QOL.
With these concerns in mind, we evaluated the association of
chronic administration of antipsychotics with cognitive function,
psychiatric symptoms, QOL, and drug-induced extrapyramidal
symptoms in long-hospitalized patients with chronic schizophrenia
and compared these measures between patients receiving typical
and atypical antipsychotics.
Methods
Subjects
In total, 144 patients with schizophrenia participated in this
study. Participants were chosen from patients who were hospital-
ized from 2000 to 2009. For patients who had been hospitalized
two times or more, data from the latest evaluation were used.
Duration of hospitalization represents the duration of hospital stay
at the time of the assessments. There was one patient in the typical
antipsychotic only group who had been hospitalized two times and
one patient in the atypical antipsychotic only group who had been
hospitalized three times. The minimum duration of hospitalization
was 2.0 years in the typical antipsychotic only group, and 1.8 years
in the atypical antipsychotic only group. Therefore, hospitalization
data suggest that all patients had a long hospital stay. All
participants met the criteria for schizophrenia according to the
ICD-10 diagnostic classification. No patient had any other
psychiatric disorder. The antipsychotic regimen had not been
changed for at least 6 months in any subject before recruitment.
All patients received one antipsychotic for at least 6 months before
recruitment. All patients were taking typical antipsychotics or
atypical antipsychotics. Typical antipsychotics included bromper-
idol (6–36 mg/day, n=4), chlorpromazine (12.5–450 mg/day,
n=11), haloperidol (0.75–33 mg/day, n=21), levomepromazine
(5–200 mg/day, n=12), and propericiazine (30–60 mg/day,
n=4). Atypical antipsychotics included aripiprazole (6–30 mg/
day, n=8), olanzapine (2.5–20 mg/day, n=27), perospirone (4–
48 mg/day, n=5), quetiapine (10–750 mg/day, n=20), and
risperidone (0.5–12 mg/day, n=32). Patients were divided into
two groups: one group (n=52) was receiving typical antipsychotics
and another group (n=92) was receiving atypical antipsychotics.
In this analysis, only patients not receiving anticholinergics for at
least 6 months before the assessment day were enrolled to
eliminate the influence of anticholinergic drugs. In the group
receiving typical antipsychotics only, 13 (25.0%) patients received
one benzodiazepine that was added to one antipsychotic, 2
(3.85%) patients were on two benzodiazepines, 2 (3.85%) patients
were on three benzodiazepines, and 1 (1.92%) patient was on four
benzodiazepines. According to the definition in this study that
polypharmacy was the concomitant use of two or more
psychotropics, 18 participants (34.62%) were receiving psychotro-
pic polypharmacy. In the group receiving atypical antipsychotics
only, 27 (29.35%) patients received a single benzodiazepine that
was added to a single antipsychotic, 5 (5.43%) patients were on
two benzodiazepines, 1 (1.09%) patient was on three benzodiaz-
epines, and 1 (1.09%) patient was on four benzodiazepines.
Thirty-four participants (36.96%) were receiving psychotropic
polypharmacy. In the group receiving typical antipsychotics only,
typical antipsychotic medication had not been switched to atypical
antipsychotic medication since the onset of schizophrenia. In the
group receiving atypical antipsychotics only, atypical antipsychotic
medication had not been switched to typical antipsychotic
medication since typical antipsychotic medication was switched
to atypical antipsychotic medication after 1996 in cases with
disease onset before 1996. In cases with disease onset after 1996,
atypical antipsychotic medication had not been switched to typical
antipsychotic medication.
The study was approved by the ethics committee of Mihara
Hospital. The content of the study and ethical considerations
related to subjects were explained to subjects, and written
informed consent to participate in the study was obtained.
Variables assessed
Variables including amount of medication, age, age at disease
onset, duration of disease, duration of hospitalization, years of
education, duration of antipsychotic medication, neurocognitive
function, psychotic symptoms, and drug-induced extrapyramidal
symptoms were assessed by clinicians. QOL was determined using
a rater-administered self-assessment scale. All variables were
assessed on the same day. Each variable was assessed a single
time. Gender, age, age at disease onset, duration of disease,
duration of hospitalization, years of education, and duration of the
antipsychotic medication were assessed based on medical charts.
All patients were taking typical or atypical antipsychotics. We
used the chlorpromazine (CPZ) equivalent (mg) to determine the
amount of typical and atypical antipsychotics each patient was
receiving [27].
Neurocognitive functioning was measured using nine items on
the Revised Hasegawa’s Dementia Scale (HDS-R). The total score
ranges from 0 to 30, with higher scores indicating better
neurocognitive function [28].
The Brief Psychiatry Rating Scale (BPRS) was used to evaluate
the severity of psychotic symptoms [29]. Each of 18 BPRS items
was scored on a 7-point scale (0 to 6), with higher scores indicating
more severe symptoms. Except for one item (mannerisms and
posturing), each of 17 items was classified into four categories. The
four categories were positive symptoms, negative symptoms,
psychological discomfort, and resistance [30]. Positive symptoms
were represented by the total score of five items (conceptual
disorganization, suspiciousness, hallucinatory behavior, unusual
thought content, disorientation). In the same way, negative
symptoms, psychological discomfort, and resistance each were
represented by the total score of three items (emotional
withdrawal, motor retardation, blunted affect), five items (somatic
concern, anxiety, guilt feelings, tension, depressive mood), and
four items (grandiosity, hostility, uncooperativeness, excitement),
respectively. The total BPRS score is the sum of scores for all
items. All raters attended a formal training course on the use of the
BPRS. Five training sessions of 3 hours each were conducted,
including an explanation of the instrument’s characteristics and
rules, exercises on BPRS application and ratings, and formal
testing of interrater reliability using videotaped interviews. During
the course of data collection, three refresher meetings were held,
discussing problems and confirming interrater reliability.
The primary dependent measure of interest was assessed using
the Schizophrenia Quality of Life Scale, translated into Japanese
(JSQLS). JSQLS is a rater-administered scale that assesses overall
QOL and functioning using 30 items rated from 0 to 4, with
higher scores reflecting worse QOL. This scale yields measures on
three subscales that address 1) dysfunction of psycho-social
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symptoms and side effects. This scale shows high sensitivity to both
changes and treatment effects and moderate-to-high correlations
with other measures of QOL, and has been shown to have
substantial sensitivity to subtle changes and treatment effects [31].
Each scale score is transformed to have a range from 0 (the best
status as measured on JSQLS) to 100 (the worst status as measured
JSQLS), with each scale calculated as follows: the scale score (SS)
equals the total of raw scores of each item in the scale (RStot),
divided by the maximum possible raw score of all items in the scale
(RSmax), all multiplied by 100: SS=(RStot/RSmax)6100 [32].
The Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS)
was used to evaluate and exclude the effects of drug-induced
extrapyramidal symptoms that could affect the severity of
symptoms in schizophrenia patients. This scale is based on nine
items rated from 0 to 4, with higher scores indicating more severe
symptoms [33].
Analytical methods
Partial correlations among scores on the psychometric tests
(HDS-R, BPRS, JSQLS, DIEPSS) and the CPZ-equivalent doses
of typical and atypical antipsychotics were calculated by Pearson
linear correlation coefficients, with correlation coefficients at a
level of 1% indicating significance. Partial correlation was
performed to investigate the relationship between CPZ-equivalent
dose and each psychometric test scores while controlling for age,
age at disease onset, duration of disease, duration of hospitaliza-
tion, years of education, duration of antipsychotic medication, and
the other psychometric tests individually. The purpose was to find
a unique variance between the two variables while eliminating the
variance from a third variable.
Partial correlation analysis was applied to indicate the CPZ-
equivalent doses of typical and atypical antipsychotics when age,
age at disease onset, duration of disease, duration of hospitaliza-
tion, years of education, duration of the antipsychotic medication,
HDS-R score, total BPRS score, BPRS subscale score, JSQLS
subscale score, and DIEPSS score were partialled out.
Correlations among clinical variables (age, age at disease onset,
duration of disease, duration of hospitalization, years of education,
and duration of antipsychotic medication) and psychometric test
scores (HDS-R, BPRS, JSQLS, DIEPSS) were calculated by
Pearson linear correlation coefficients, with correlation coefficients
at a level of 1% indicating significance.
The student t-test was used to compare scores obtained from
CPZ-equivalent dose of antipsychotics, age, age at disease onset,
duration of disease, duration of hospitalization, years of education,
duration of the antipsychotic medication and psychometric tests
between patients receiving typical and atypical antipsychotics.
Differences were considered significant at P,0.01. Statistical
analyses were performed using PASW Statistics 18.0 software
(SPSS Japan Inc., Tokyo, Japan).
Results
Characteristics of subjects are shown in Table 1. All subjects
were Japanese. The mean age of the 52 patients in groups
receiving typical was 54.9 years, and 32.6% were male. The mean
age of the 92 patients in groups receiving atypical was 59.1 years,
and 39.1% were male. Variables assessed included CPZ-equiva-
lent dose of antipsychotics, age, age at disease onset, duration of
disease, duration of hospitalization, years of education, and
duration of the antipsychotic medication. We compared each
variable assessed between groups receiving typical and atypical
antipsychotics. No significant differences in CPZ-equivalent dose
of antipsychotics, age, age at disease onset, duration of disease,
duration of hospitalization, years of education, and duration of the
antipsychotic medication were seen between groups.
The correlations between each psychometric test score and
CPZ-equivalent doses of typical antipsychotics and atypical
antipsychotics are shown in Tables 2 and 3. There were no
significant relationships between the equivalent doses of typical or
atypical antipsychotics and total HDS-R score. Significant positive
correlations were found between CPZ-equivalent doses of typical
and atypical antipsychotics and total BPRS score as well as the
BPRS subscale score for positive symptoms. The CPZ-equivalent
doses of typical but not atypical antipsychotics showed a significant
positive correlation with the JSQLS subscale score for the
dysfunction of psycho-social activity. The CPZ-equivalent doses
of typical antipsychotics but not atypical antipsychotics were
correlated with the DIEPSS score.
The correlations among clinical variables and psychometric test
scores are shown in Tables 4 and 5. There were significant positive
correlations among age, duration of disease, duration of hospital-
Table 1. Patients’ characteristics (mean 6 SD).
Typical antipsychotic only group
Atypical antipsychotic
only group
Between group p
value
No. of patients 52 92
Gender % male 32.6 39.1
CPZ equivalent dose of antipsychotics (mg/day) 561.86266.2 577.96282.7 0.432
Age (years) 54.9613.1 59.1616.9 0.102
Age at disease onset (years) 24.368.1 24.668.2 0.901
Duration of disease (years) 18.8610.1 21.7612.1 0.864
Duration of hospitalization (years) 10.168.9 (minimum duration: 2.0,
maximum duration: 23.1)
8.366.6 (minimum duration: 1.8,
maximum duration: 28.3)
0.518
Years of education (years) 10.562.2 11.262.1 0.440
Duration of the antipsychotic medication (years) 17.969.6 19.1612.8 0.223
Scores on evaluation scales are mean values (standard deviation).
Student’s t-test.
CPZ, chlorpromazine.
doi:10.1371/journal.pone.0037087.t001
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groups. In addition, significant positive correlations were found
between the DIEPSS score and the JSQLS subscale for
dysfunction of psycho-social activity, and between BPRS negative
symptoms or psychological discomfort or resistance and all JSQLS
subscales, respectively.
We compared each score of the psychometric tests between
groups receiving typical and atypical antipsychotics. No significant
differences in total HDS-R score were seen between groups. The
total BPRS scores, BPRS subscale score for positive symptoms, the
JSQLS subscale score for dysfunction of psycho-social activity, and
the DIEPSS score were significantly higher in patients receiving
typical antipsychotics than in patients receiving atypical antipsy-
chotics (Table 6).
Discussion
This study was designed to investigate the relationship between
long-term administration of antipsychotics and clinical and
psychometric variables for schizophrenia inpatients. A further
aim was to elucidate the differential influence of typical and
atypical antipsychotics on QOL or other symptoms among long-
stay inpatients.
The BPRS scores were correlated with the CPZ-equivalent
doses of typical antipsychotics and atypical antipsychotics in this
study. These were positive significant correlations among the
BPRS scores for positive symptoms and the doses of typical and
atypical antipsychotics. In these correlations, a high dose of
antipsychotics seems to reflect positive symptoms. On the other
hand, these correlations might imply that patients stabilized at a
lower dose of antipsychotic medication are more likely to have
fewer symptoms than those who are receiving a higher dose of
medication. However, because this study was cross-sectional,
causality of relationships between positive symptoms and the doses
of typical and atypical antipsychotics could not be determined.
Significant differences were observed in BPRS subscales for
positive symptoms between patients receiving typical and atypical
antipsychotics. Psychiatric symptoms generally tended to be more
intense among patients who received typical antipsychotics
compared with those who received atypical antipsychotics. One
possible reason for this finding may be the tendency to continue
prescribing typical antipsychotics rather than switching to atypical
antipsychotics when psychiatric symptoms persist [4].
A significant positive correlation was found between the
subscale score of JSQLS for dysfunction of psycho-social activity
and CPZ-equivalent doses of typical but not atypical antipsychot-
ics. Examination of antipsychotic agents and QOL showed that
chronic administration of antipsychotic agents increased the levels
of feelings of difficulty mixing in social situations, and feeling
worried about the future (measured by the JSQLS subscale for the
dysfunction of psycho-social activity) in a dose-dependent manner.
In regard to the association of typical antipsychotics with the
subscale score of JSQLS for dysfunction of psycho-social activity,
we viewed the association of typical antipsychotics with extrapy-
ramidal symptoms. The present results suggest that the DIEPSS
total score is positively correlated with the CPZ-equivalent doses of
typical antipsychotics and that there were significant differences in
the DIEPSS score between patients treated with typical antipsy-
chotics and atypical antipsychotics. Furthermore, the DIEPSS
score is positively correlated with the JSQLS subscale for
dysfunction of psycho-social activity (Table 4, 5). In addition,
Crossley et al. reported that patients receiving typical antipsychot-
ics experienced more extrapyramidal side effects than patients
receiving atypical antipsychotics [34]. The influence of extrapy-
ramidal adverse effects on QOL has already been documented.
Ritsner et al. used the Montgomery-Asberg Depression Rating
Scale (MADRS), the Talbieh Brief Distress Inventory (TBDI), the
Abnormal Involuntary Movement Scale (AIMS), and the Quality
of Life Enjoyment and Satisfaction Questionnaire in schizophrenia
patients and reported that the depression score on the TBDI and
the score on the AIMS were predictors of poor QOL [35]. Awad
et al. used the PANSS, the Hillside Akathisia scale, and the Drug
Attitude Inventory to show that subjective QOL is greatly
influenced by psychopathology, akathisia, and patients’ subjective
tolerance of medications, and concluded that effort should be
directed toward effective control of psychotic symptoms and
minimizing the side effects of antipsychotic drugs to improve the
QOL of patients with schizophrenia [24]. Therefore, we thought
that patients with extrapyramidal symptoms induced by typical
antipsychotics have more subjective discomfort with respect to
Table 6. Comparison of each scale between patients receiving typical and atypical antipsychotics.
Typical antipsychotic only
group
Atypical antipsychotic only
group Between group p value
HDS-R total score 19.964.6 21.666.8 0.101
BPRS total score 29.3616.1 20.8610.4 ,0.001 *
BPRS positive symptoms 12.366.7 7.964.1 0.001 *
BPRS negative symptoms 4.763.3 5.163.6 0.940
BPRS psychological discomfort 5.563.5 5.163.1 0.894
BPRS resistance 2.661.5 2.961.6 0.964
JSQLS dysfunction of psycho-social activity 36.6619.1 25.9612.7 0.008 *
JSQLS dysfunction of motivation and energy 35.2617.5 38.0618.8 0.535
JSQLS level of symptoms and side-effect 26.3618.3 24.0615.7 0.602
DIEPSS 5.462.1 4.662.0 0.009 *
Scores on evaluation scales are mean values (standard deviation).
Student’s t-test.
*Correlation is significant at the 1% level (two sided).
BPRS, Brief Psychiatry Rating Scale; DIEPSS, The Drug-Induced Extrapyramidal Symptoms Scale; HDS-R, Revised Hasegawa’s dementia scale; JSQLS, the Schizophrenia
Quality of Life Scale, a Japanese version.
doi:10.1371/journal.pone.0037087.t006
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Though this study has something to add about partial
correlation, it is assumed that there would be significant
relationships among the variables, like what was stated for JSQLS
and DIEPPS. Therefore, correlation was performed to investigate
the relationship among clinical variables (age, age at disease onset,
duration of disease, duration of hospitalization, years of education,
and duration of antipsychotic medication) and psychometric test
scores. It was evident that there were significant positive
correlations among duration of disease, duration of hospitaliza-
tion, and duration of the antipsychotic medication. On the other
hand, there were significant positive correlations between the
DIEPSS score and the JSQLS subscale for dysfunction of psycho-
social activity, and between BPRS negative symptoms or
psychological discomfort or resistance and all JSQLS subscales,
respectively (Table 4, 5). This would justify partial correlations that
were performed to investigate the relationship between the CPZ-
equivalent dose and each psychometric test scores. Despite the
relationships between DIEPPS and JSQLS subscale for dysfunc-
tion of psycho-social activity in patients, it is suggested that the
partial correlation showed that controlling for DIEPPS did not
lower the strength of the relationship between typical antipsychotic
dose and JSQLS subscale for dysfunction of psycho-social activity.
In the same way, despite the relationships between BPRS and
JSQLS in patients, the partial correlation showed that controlling
for BPRS did not lower the strength of the relationship between
typical antipsychotic dose and JSQLS. That is, the relationship
between typical antipsychotic dose and JSQLS is not due to
patients’ experience of extrapyramidal adverse effects and
symptoms.
In the present study, partial correlation analysis was applied to
indicate the CPZ-equivalent doses of typical and atypical
antipsychotics when duration of the antipsychotic medication
was partialled out. Ritsner et al. [26] reported that the longer the
antipsychotic treatment, the better the QOL outcomes. Therefore,
we viewed the difference of duration of the antipsychotic
medication between the group receiving typical antipsychotics
only and the group receiving atypical antipsychotics only. There
was no significant difference between the group receiving typical
antipsychotics only and the group receiving atypical antipsychotics
only. Furthermore, there were no differences in the results when
duration of antipsychotic medication was partialled out. There-
fore, we could exclude the influence of duration of the
antipsychotic medication on the poorer outcome of groups treated
with typical antipsychotic medication.
Moreover, Ritsner et al. [26] also reported that duration of
treatment is a strong factor that may reveal different QOL
outcomes for patients receiving atypical versus typical antipsy-
chotics. In the present study, the JSQLS subscale score for
dysfunction of psycho-social activity was significantly higher in
patients receiving typical antipsychotics than in patients receiving
atypical antipsychotics. The above-mentioned results are similar to
their results. In our study, it can be suggested that a difference in
receiving atypical versus typical antipsychotics influenced QOL
without influencing the duration of treatment.
In terms of the relation of frequent relapses and the impact of
acute deterioration of symptoms at relapse on social function,
there were no differences in the number of two or more
hospitalizations between the typical antipsychotic only group
and the atypical antipsychotic only group. In addition, the
minimum duration of hospitalization was 2.0 years in the typical
antipsychotic only group, and 1.8 years in the atypical antipsy-
chotic only group. Because hospitalization data suggest that all
patients had a long hospital stay, it is suggested that acute
deterioration of symptoms seen within several days of the
beginning of hospitalization did not influence our study results.
Ritsner et al. [26] found that QOL outcomes were not related to
age and education. In the present study, there were no significant
differences in these variables between the group receiving typical
antipsychotics only and the group receiving atypical antipsychotics
only. Furthermore, there were no differences in the results when
age and education were partialled out.
With regard to the relationship between atypical antipsychotics
and cognitive function, Keefe et al. [36] showed that atypical
antipsychotics significantly improved cognitive dysfunction in
seven of eight categories (attention, executive function, working
memory, learning and memory, visuospatial analysis, verbal
fluency, digit-symbol substitution, and fine motor function)
compared with typical antipsychotics. However, as shown in
Table 6, no significant difference in the scores of cognitive function
by HDS-R was observed between patients receiving typical and
atypical antipsychotics in our study. HDS-R may not have had
sufficient sensitivity to detect subtle differences in cognitive
functioning between the two antipsychotic-treated groups. In
regard to the limitation on clinical assessment of cognitive function
in our study, Keefe et al. suggested that clinical assessment of
cognitive deficits on the Mini Mental Status Examination (MMSE)
using the same items as the HDS-R is not a viable alternative to
neuropsychological testing to obtain information about cognitive
functioning in schizophrenia [37]. Their findings limit the
interpretation of the present results. To elucidate the influence
of cognitive dysfunction on QOL, further studies using neuropsy-
chological tests such as the Brief Assessment of Cognition in
Schizophrenia [38] are necessary.
There is a major limitation to the current study: due to the
naturalistic design, drug administration was not controlled before
the study, and therefore there were no baseline data at the time of
treatment assignment. Although the current results are statistically
robust, they should be interpreted with caution, as only an
association and not causality can be inferred. At least in part, these
limitations have been resolved during the current 6-month follow-
up stage of the study. In addition, this study should be interpreted
with caution due to certain methodological limitations. First,
because the study was cross-sectional, causality of relationships
among clinical variables could not be determined. Second, we
statistically assessed multiple evaluation items between the group
receiving typical antipsychotics only and the group receiving
atypical antipsychotics only. However, multiple comparisons were
not conducted in our study because each evaluation item was
examined individually in this study. Further studies should take
these factors into account to determine any statistical differences
between two or more groups while evaluating multiple items. With
these limitations in mind, this study provides evidence to support
the hypothesis that long-term administration of typical antipsy-
chotics has unfavorable associations with psychiatric symptoms,
QOL, and drug-induced extrapyramidal symptoms in patients
with chronic schizophrenia.
In summary, as shown in Tables 2 and 3, involvement of typical
antipsychotics, but not atypical antipsychotics, was specific to the
JSQLS subscale score for dysfunction in psycho-social activity. In
this cross-sectional study, typical antipsychotics appear to have a
stronger association with negative QOL than atypical antipsy-
chotics. In particular, feelings of difficulties in social situations and
feeling worried about the future are related to the JSQLS subscale
for the dysfunction of psycho-social activity. Therefore, it could be
suggested that chronic administration of typical antipsychotics had
an unfavorable impact on feelings of difficulties in social situations
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schizophrenia. Furthermore, chronic administration of typical
antipsychotics induces more side effects that include extrapyrami-
dal symptoms. Based on the results of the present study, the
necessity to consider avoiding chronic administration of typical
antipsychotics and promptly reducing their doses can be
emphasized. We hope that reports on the risks associated with
chronic administration of typical antipsychotics, which urge
clinicians to switch from typical antipsychotics to monotherapy
with atypical antipsychotics, will continue to accumulate.
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